Our clinical trials aim to determine how drugs and other therapies can prevent or treat medical problems seen in individuals with NF1 and NF2.
Search for additional current clinical trials at clinicaltrials.gov →
Learn about the NF Clinical Trials Consortium at UAB →
NF1 Trials
- Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 (DoDNAC)
- Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation
- Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
- Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- NF-1, Nutraceutical Intervention
- Natural History Study of Patients with Neurofibromatosis Type 1*
- Neurofibromatosis (NF) Registry Portal
- Resiliency Training in Adolescents With NF1 and NF2
- Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1*
- Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
- DPCP to Treat Cutaneous Neurofibromas Associated With NF1
- Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
- Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
- HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy*
- Natural History Study of Cutaneous Neurofibromas in People With NF1 (cNF Natural Hx)
- Photodynamic Therapy for Benign Dermal Neurofibromas – Phase II
- Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma*
- Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas*
- AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors*
- Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
- Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
- Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (RENEU)*
- Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas*
- Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
- Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas*
- Phase I Trial of Turalio(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
- Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI)*
- PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1*
- Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway*
- Treatment of NF1-related Plexiform Neurofibroma With Trametinib (plexifpc)*
- US Selumetinib Registry
- A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
- A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
- A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
- A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
- EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
- Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
- Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
- Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma*
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors*
- Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
- Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study*
- Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
- Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
- Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors*
- A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
- Glioma Developmental and HyperActive Ras Tumor (DHART) Board
- Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma*
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
- A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
- Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
- B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults*
- Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
- Diagnosis of Pheochromocytoma
- Familial Investigations of Childhood Cancer Predisposition (SJFAMILY)
- GIST: Assessment of Tumor Mutations and TKI Plasma Exposure
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma*
- A Study of Avutometinib for People With Solid Tumor Cancers
- A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
- Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia*
NF2 Clinical Trial
- CI Following VS Removal or Labyrinthectomy
- Doxycycline in Cutaneous Schwannoma (NF2)
- Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma*
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (INTUITT-NF2)
- Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)*
- Study of Aspirin in Patients With Vestibular Schwannoma
- Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)
- Vestibular Outcomes in Vestibular Schwannoma (VOVS)*
- Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
- Carbon Ion Radiotherapy for Atypical Meningiomas (MARCIE)*
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas (POPLAR-NF2)
- Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (INTUITT-NF2)
- Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma*
- Predictive Factors of Visual Recovery After Paraoptic Tumors Removal (PRONOPTIC)
- A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma
- A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
- Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas*
*Studies that are active but not recruiting